Notoginsenoside R1
Based on 4 publication(s) in Google Scholar
Notoginsenoside R1 (Sanchinoside R1), a saponin, is isolated from P. notoginseng. Notoginsenoside R1 exhibits anti-oxidation, anti-inflammatory, anti-angiogenic, and anti-apoptosis activities. Notoginsenoside R1 provides cardioprotection against ischemia/reperfusion (I/R) injury. Notoginsenoside R1 also provides neuroprotection in H2O2-induced oxidative damage in PC12 cells.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.68%
- CAS 番号: 80418-24-2
- 分子式: C47H80O18
- 分子量:933.13
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-N0045
Ginsenoside Rg1Apoptosis Inducer -
HY-N0431
Astragaloside IVMMP Inhibitor -
HY-N0039
Ginsenoside Rb1Autophagy Inducer -
HY-N0135
Tanshinone IIAVEGFR Inhibitor -
HY-N0044
Ginsenoside ReEndogenous Metabolite -
HY-N0145
Puerarin5-HT Receptor Antagonist -
HY-N1362
Salvianolic acid BAntioxidant -
HY-N0293
PaeoniflorinHSP Activator -
HY-N0197
BaicalinAutophagy Inducer -
HY-N0196
BaicaleinXanthine Oxidase Inhibitor -
HY-N0109
SalidrosideProlyl Endopeptidase Inhibitor -
HY-N0005
Curcuminp300 Histone Acetylatransferase Inhibitor
MedChemExpress（MCE）の使用を引用している文献 Notoginsenoside R1
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
-
IF
-
In Vivo Efficacy Study
-
WB
生物活性
製品説明
体外実験
Notoginsenoside R1 (2.5-80 μM; 24 h) inhibits the hypoxia-reoxygenation (H/R)-induced cell death, intracellular ROS accumulation, and mitochondrial membrane depolarization in H9c2 cardiomyocytes[1].
?
Notoginsenoside R1 (5-20 μM; 24 h) inhibits the H/R-induced H9c2 cardiomyocytes apoptosis in a concentration-dependent manner[1].
?
Notoginsenoside R1 (1-100 μM; 24 h) dose-dependently protects PC12 cells and primary neurons from Aβ-induced cell death and apoptosis[2].
?
Notoginsenoside R1 (10 μM; 24 h) inhibits Aβ25-35-induced ROS production, mitochondrial damage and MAPK activation in PC12 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley (SD) rats (200-250 g)[3]
-
Dosage:5 mg/kg/h
-
Administration:Infused 20 min before LPS infusion via the right jugular vein
-
Result:Ameliorated the LPS-induced reduction in the mesenteric venular shear rate to some extent.
Attenuated the LPS-induced adhesion of leukocytes to the venular wall.
Inhibited mast cell degranulation and cytokine elevation.
化学情報
-
CAS 番号 80418-24-2
-
性状 Solid
-
分子量 933.13
-
分子式 C47H80O18
-
Color White to off-white
-
SMILES
C[C@]([C@@](C[C@H]1O)([H])[C@]2(CC[C@@H]3O)C)(C[C@H](O[C@@](O[C@H](CO)[C@@H](O)[C@@H]4O)([H])[C@@H]4O[C@@](OC[C@@H](O)[C@@H]5O)([H])[C@@H]5O)[C@@]2([H])C3(C)C)[C@]6([C@@]1([H])[C@]([C@@](CC/C=C(C)/C)(C)O[C@@H]([C@@H]([C@@H](O)[C@@H]7O)O)O[C@@H]7CO)([H])CC6)C
-
別名
ノトギンセノシドR1; Sanchinoside R1; Sanqi glucoside R1
-
Structure Classification
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
-
Front Cell Neurosci
Notoginsenoside R1-Induced Neuronal Repair in Models of Alzheimer Disease Is Associated With an Alteration in Neuronal Hyperexcitability, Which Is Regulated by Nav. [Abstract]2020 Sep 4:14:280. PMID: 33088260
Notoginsenoside R1 purchased from MedChemExpress. Usage Cited in: Front Cell Neurosci. 2020 Sep 4:14:280. [Abstract]
Effect of Notoginsenoside R1 (R1; 5 μM) on the expression, location, and cleavage status of sodium channel proteins after Aβ1-42 treatment.
Notoginsenoside R1 purchased from MedChemExpress. Usage Cited in: Front Cell Neurosci. 2020 Sep 4:14:280. [Abstract]
Effect of Notoginsenoside R1 (R1, 5 μM) on Aβ1-42 (5 μM)–induced neuron viability determined using MTT assay. Cell viability of cultured neurons treated with different groups at 0 h, 24 h, 48 h, 72 h, and 96 h.
Notoginsenoside R1 purchased from MedChemExpress. Usage Cited in: Front Cell Neurosci. 2020 Sep 4:14:280. [Abstract]
Notoginsenoside R1 (R1, 5 μM) was responsible for reducing abnormal excitability in Aβ1-42–induced neurons.
Notoginsenoside R1 purchased from MedChemExpress. Usage Cited in: Front Cell Neurosci. 2020 Sep 4:14:280. [Abstract]
Notoginsenoside R1 (R1, 5 mg/kg; i.g.; once daily for 6 months) partially improved the Marris Water Maze (MWM) test behavior in APP/PS1 mice.
-
Animals (Basel)
Notoginsenoside R1 Inhibits Porcine Deltacoronavirus Infection In Vitro by Restoring SERCA2-Mediated Calcium Homeostasis. [Abstract]2026 Jun 14;16(12):1836. PMID: 42353446 -
Notoginsenoside R1 purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Jul 12.
Notoginsenoside R1 (NGR1, 2.5-20 μM; 24 h) treatment did not significantly affect the cell viability of PPARγ/PPRE-transfected HT22 cells.
Notoginsenoside R1 purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Jul 12.
Notoginsenoside R1 (NGR1, 2.5-20 μM; 24 h) treatment notably increased the luciferase activity in the PPARγ/PPRE-transfected HT22 cells.
Notoginsenoside R1 purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Jul 12.
Notoginsenoside R1 (NGR1, 10 µM; 24 h) treatment promoted GLUT4 membrane translocation in primary mouse hippocampal neurons. Scale bar = 20 μm.
Notoginsenoside R1 purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Jul 12.
Notoginsenoside R1 (NGR1, 10-80 mg/kg; i.g.; 16 weeks) treatment dramatically decreased the levels of fasting blood glucose in APP/PS1xdb/db mice in a dose-dependent manner.
溶剤 & 溶解度
体外:
DMSO : 100 mg/mL (107.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.68 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.68 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
プロトコル
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
純度とドキュメンテーション
-
データシート (287 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Yu Y, et, al. Cardioprotective effects of Notoginsenoside R1 against ischemia/reperfusion injuries by regulating oxidative stress- and endoplasmic reticulum stress- related signaling pathways. Sci Rep. 2016 Feb 18;6:21730. [Content Brief]
[2]. Ma B, et, al. Notoginsenoside R1 attenuates amyloid-β-induced damage in neurons by inhibiting reactive oxygen species and modulating MAPK activation. Int Immunopharmacol. 2014 Sep;22(1):151-9. [Content Brief]
[3]. Sun K, et, al. Protective effects of ginsenoside Rb1, ginsenoside Rg1, and notoginsenoside R1 on lipopolysaccharide-induced microcirculatory disturbance in rat mesentery. Life Sci. 2007 Jul 19;81(6):509-18. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.0717 mL | 5.3583 mL | 10.7166 mL | 26.7916 mL |
| 5 mM | 0.2143 mL | 1.0717 mL | 2.1433 mL | 5.3583 mL | |
| 10 mM | 0.1072 mL | 0.5358 mL | 1.0717 mL | 2.6792 mL | |
| 15 mM | 0.0714 mL | 0.3572 mL | 0.7144 mL | 1.7861 mL | |
| 20 mM | 0.0536 mL | 0.2679 mL | 0.5358 mL | 1.3396 mL | |
| 25 mM | 0.0429 mL | 0.2143 mL | 0.4287 mL | 1.0717 mL | |
| 30 mM | 0.0357 mL | 0.1786 mL | 0.3572 mL | 0.8931 mL | |
| 40 mM | 0.0268 mL | 0.1340 mL | 0.2679 mL | 0.6698 mL | |
| 50 mM | 0.0214 mL | 0.1072 mL | 0.2143 mL | 0.5358 mL | |
| 60 mM | 0.0179 mL | 0.0893 mL | 0.1786 mL | 0.4465 mL | |
| 80 mM | 0.0134 mL | 0.0670 mL | 0.1340 mL | 0.3349 mL | |
| 100 mM | 0.0107 mL | 0.0536 mL | 0.1072 mL | 0.2679 mL |
Notoginsenoside R1 関連分類
HY-N0615 関連分類
Powered by Bioz
Keywords
- Notoginsenoside R1
- 80418-24-2
- Sanchinoside R1
- Sanqi glucoside R1
- Notoginsenoside R 1
- Notoginsenoside R-1
- Sanchinoside R 1
- Sanchinoside R-1
- Sanqi glucoside R1
- Sanqi glucoside R 1
- Sanqi glucoside R-1
- Amyloid-β
- Apoptosis
- saponin
- anti-oxidation
- anti-inflammatory
- anti-angiogenic
- anti-apoptosis,cardioprotection
- I/R
- neuroprotection
- Inhibitor
- inhibitor
- inhibit